Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
VENTANA is a "window-of-opportunity" trial that will explore whether, similar to CDK4/6
inhibitors, Oral Metronomic Vinorelbine in combination with Letrozole induces a superior
anti-proliferative effect than Letrozole alone.